Skip to main content
. 2016 Jul 7;6:29348. doi: 10.1038/srep29348

Figure 4. In vivo therapeutic efficacies of r-As4S4, e-As4S4, and ATRA.

Figure 4

(a) Survival curve of AML mice treated with saline (blue line), r-As4S4 (red line), e-As4S4/1:15–60 (green line), or ATRA (purple line) (n = 8). The log-rank test (Mantel-Cox) was used to assess statistical significance: e-As4S4 vs. saline (P < 0.0001), e-As4S4 vs. r-As4S4 (P = 0.0264), e-As4S4 vs. ATRA (P = 0.0049), r-As4S4 vs. ATRA (P = 0.2082). (b) Body weight change curves of AML mice treated with saline (blue line), r-As4S4 (red line), e-As4S4/1:15–60 (green line), or ATRA (purple line) (n = 8). NOD/SCID mice were injected intravenously with HL-60 cells (1 × 106 cells/mouse) after 250 cGy γ-irradiation. After 20 days, treatment was started, with intragastric administration of saline, r-As4S4 (1.8 mg per mouse per time, twice per day), e-As4S4/1:15–60 (28.8 mg per mouse per time, twice per day), or ATRA (0.18 mg per mouse per time, once per day).